Last reviewed · How we verify
paclitaxel, carboplatin and bevacizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
paclitaxel, carboplatin and bevacizumab (paclitaxel, carboplatin and bevacizumab) — Spanish Lung Cancer Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| paclitaxel, carboplatin and bevacizumab TARGET | paclitaxel, carboplatin and bevacizumab | Spanish Lung Cancer Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- paclitaxel, carboplatin and bevacizumab CI watch — RSS
- paclitaxel, carboplatin and bevacizumab CI watch — Atom
- paclitaxel, carboplatin and bevacizumab CI watch — JSON
- paclitaxel, carboplatin and bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). paclitaxel, carboplatin and bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-carboplatin-and-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab